Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

CME Group (CME) February ADV Drops At Six Products Lines

Published 03/04/2019, 08:45 PM
Updated 07/09/2023, 06:31 AM

CME Group Inc. (NASDAQ:CME) reported average daily volume (ADV) for February 2019. The month recorded ADV of 19 million contracts per day, down 27.3% year over year. However, it increased 7% from January. The company witnessed a decrease in ADV in all six product lines. Options volume increased 3.5 million contracts per day, down 42% year over year.

Energy volume of 2.3 million contracts decreased 17%. Interest rate volume of 11 million contracts per day declined 30% while Equity index volume of 2.7 million contracts per day decreased 45%. However, Metals volume of 0.5 million contracts per day declined 24% whereas Foreign exchange volumes contracted 30% to 0.8 million contracts per day. Agricultural volume of 1.7 million contracts per day too witnessed a decline of 13% year over year.

Recently, securities exchange Nasdaq Inc. (NASDAQ:NDAQ) and MarketAxess Holdings Inc. (NASDAQ:MKTX) also posted February volumes. MarketAxess’ trading volume came in at $167 billion while Nasdaq reported options and futures volume of 127.6 million contracts for February.

Volumes at CME Group were backed by solid operating leverage, which helped it maintain a solid market share of about 90% in global futures trading and clearing services. ADV increased 18% in 2018, with record volumes in four product lines. Expansion of futures products in the emerging markets plus an increase in non-transaction related opportunities as well as OTC offerings should continue to contribute modestly to its top-line growth in the years ahead.

Increasing electronic trading volume adds scalability and hence leverage to CME Group’s operating model. Efforts to expand and cross-sell through strategic alliances, acquisitions, new product initiatives and a strong global presence should also drive growth.

Shares of CME Group have underperformed the industry year to date. While the stock has declined 4.1%, the industry has registered a 1.7% rise in the said time frame. CME Group currently carries a Zacks Rank #3 (Hold).



A Stock to Consider

A better-ranked stock from the finance sector is Cincinnati Financial Corporation (NASDAQ:CINF) , sporting Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Cincinnati Financial provides property and casualty insurance products in the United States. The company pulled off a positive surprise in three of the trailing four quarters, with the average earnings surprise being 18.08%.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>



Cincinnati Financial Corporation (CINF): Free Stock Analysis Report

CME Group Inc. (CME): Free Stock Analysis Report

Nasdaq, Inc. (NDAQ): Free Stock Analysis Report

MarketAxess Holdings Inc. (MKTX): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.